Published in Cancer Lett on February 12, 2015
Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine (2017) 0.75
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma. Oncotarget (2016) 0.75
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
Neuroblastoma. Lancet (2007) 10.61
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery (1998) 2.07
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos (2000) 1.67
Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet (1997) 1.48
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res (2006) 1.29
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev (2010) 1.16
Camptothecins: a review of their development and schedules of administration. Eur J Cancer (1998) 1.12
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res (1997) 1.04
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol (2009) 1.03
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res (2010) 0.99
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res (2010) 0.93
Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice. Acta Pharm (2009) 0.92
Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res (2005) 0.91
Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs (1997) 0.90
Targeting liposomes toward novel pediatric anticancer therapeutics. Pediatr Res (2010) 0.89
Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment. Tumori (2008) 0.89
Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies. J Control Release (2012) 0.88
Therapeutic targets for neuroblastomas. Expert Opin Ther Targets (2014) 0.87
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm (2011) 0.86
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol (2011) 0.86
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations. Cancer Res (2004) 0.86
MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. Int J Pharm (2014) 0.85
Liposome-mediated therapy of neuroblastoma. Methods Enzymol (2009) 0.83
Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials (2015) 0.82
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) (2013) 0.81
SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan. Int J Pharm (2014) 0.80
Preclinical antitumor activity of a nanoparticulate SN38. Invest New Drugs (2013) 0.79
The clinical pharmacology of topoisomerase I inhibitors. Semin Hematol (1998) 0.78
Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies. Drug Deliv (2014) 0.78
Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. J Pharm Sci (2011) 0.77